area-under-the-curve (AUC) monitoring.
In the present investigation, we used two independent data sets: group 1, 101 AUG profiles from 77 stable renal-transplant patients, which included a 5-h sample in addition to the usual 0-, 2-, 4-, 6-, 10-, 14-, and 24-h samples; and group 2, 100 
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where E% is the error or deviation from a proportionate relation of dose to CsA concentration; C and C are the concentrations (e.g.,
or individual concentration) after and before the change in dosing, respectively; f is the proportionality factor that describes the change in the oral dose rate from D1 (pre) to D2 (post). f is zero when the dose is not changed: 
